{"entity":{"id":"nct06922357","kind":"trial","name":"A Phase I/II of HRS-6719 in Patients With Advanced/Metastatic Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of HRS-6719 in advanced solid tumours, run by Shandong Suncadia Medicine Co., Ltd., now recruiting.","summary":"A Phase I/II of HRS-6719 in Patients With Advanced/Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06922357 by Shandong Suncadia Medicine Co., Ltd., with 120 participants planned, started 2025-04-24 and due to reach its primary completion in 2027-12. Interventions recorded: HRS-6719.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06922357","url":"https://clinicaltrials.gov/study/NCT06922357"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06922357","phase":"1/2","setting":"A Phase I/II, Open-label, Multi-centre Study Evaluating the Safety,Tolerability,Pharmacokinetic (PK), Pharmacodynamics, and Preliminary Efficacy of HRS-6719 in Patients With Advanced/Metastatic Solid Tumors With MTAP Deficiency","sponsor":"Shandong Suncadia Medicine Co., Ltd.","enrolled":120,"outcomes":[]},"route":"/trials/nct06922357/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}